August 18 - CTI's Second Quarter 2008 Financial Results
August 12 - CTI Announces that the EORTC Completes Enrollment in Phase II Clinical Trial of Brostallicin as First-Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
August 5 - Craig W. Philips Takes Helm at CTI
July 22 - CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
July 15 - 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
More Press Releases
